期刊
JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 395, 期 -, 页码 62-70出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2018.09.033
关键词
Mitochondria; Central nervous system; Drug delivery; Alzheimer's disease
资金
- National Research Foundation of Korea (NRF) - Korean government [NRF-2017R1A2B4012636]
- Gachon University Research Grant [2018-0314]
Alzheimer's Disease (AD) is one of the most common age-related neurodegenerative diseases in the developed world. Treatment of AD is particularly challenging as the drug must overcome the blood brain barrier (BBB) before it can reach its target. Mitochondria are recognized as one of the most important targets for neurological drugs as the organelle is known to play a critical role in diverse cellular processes such as energy production and apoptosis regulation. Mitochondrial targeting was originally developed to study mitochondrial dysfunction and the organelles interaction with other sub-cellular organelles. The purpose of this review is to provide an overview of mitochondrial dysfunction and its role in late onset AD pathology. We then highlight recent antioxidant and enzymatic treatments used to alleviate mitochondrial dysfunction. Finally, we describe current applications of targeted mitochondrial delivery in the treatment of AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据